small molecule

CAMCEVI ETM

LEUPROLIDE MESYLATE

Loss of exclusivityJanuary 2039latest FDA-listed patent expiry

CompanyAccord Biopharma →View the full company profile on CliffBio

Drug detail

Brand name	CAMCEVI ETM
Active ingredient	LEUPROLIDE MESYLATE
Strength	EQ 21MG BASE
Dosage form	EMULSION
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	August 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
11717555	January 2039	product
12133878	December 2037	product
9572857	August 2029	product
9744207	January 2027	product
10646572	January 2027	product

Regulatory exclusivity

Code	Expires
NS	August 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Accord Biopharma